Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: n/a
Number of Subjects: 46
Medication: Ocrelizumab (Ocrevus®), Alemtuzumab (Lemtrada®), Cladribine (Mavenclad®), Dimethyl fumarate (Tecfidera®), Fingolimod (Gilenya®), Natalizumab (Tysabri®
Location: Massachusetts
Institutions: Massachusetts General Hospital
165 Cambridge St, 6th Floor
Boston, MA 02114
Contact Information
Dylan Rice
(617) 643-2947
drice2@partners.org